R. Somers

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al. · Journal of Clinical Oncology · 1999 · 570 citations

Medicine, Oncology, Pharmacology +16

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Armando Santoro, T Türsz, Henning T. Mouridsen et al. · Journal of Clinical Oncology · 1995 · 530 citations

Medicine, Oncology, Pharmacology +14

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

Carlos Graux, Jan Cools, Cindy Melotte et al. · Nature Genetics · 2004 · 422 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +11

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

V. Bramwell, M Burgers, R. S. Sneath et al. · Journal of Clinical Oncology · 1992 · 317 citations

Medicine, Oncology, Surgery +17

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

Umberto Tirelli, D. Errante, M. van Glabbeke et al. · Journal of Clinical Oncology · 1998 · 219 citations

Medicine, Geriatric Medicine, Oncology +15